ADMA BIOLOGICS, INC. (ADMA)

↓ Download CSV

CIK 0001368514 · Nasdaq · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, ADMA BIOLOGICS, INC. reported revenue of $510.17M, up 19.6% from the prior year. The company was profitable, with a net margin of 28.8% and a gross margin of 57.4%. It held $624.24M in total assets against $146.92M in total liabilities.

Key ratios (FY2025)

57.4%
Gross margin
37.5%
Operating margin
28.8%
Net margin
30.8%
Return on equity
+19.6%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$510.17M$426.45M$258.21M$154.08M$80.94M$42.22M
Cost of Revenue$217.41M$206.90M$169.27M$118.81M$79.77M$61.29M$39.50M$42.19M$29.16M$1.61M
Gross Profit$292.76M$219.55M$88.94M$35.27M$1.17M-$19.07M-$25.21M-$6.40M$4.30M
Operating Income$191.44M$138.98M$21.63M-$39.37M-$58.37M-$64.91M-$41.42M-$60.29M-$39.31M-$17.33M
Net Income$146.93M$197.67M-$28.24M-$65.90M-$71.65M-$75.75M-$48.28M-$65.74M-$43.76M-$19.52M
EPS (Diluted)$0.60$0.81$-0.13$-0.33$-0.51$-0.88
Total Assets$624.24M$488.68M$329.18M$348.46M$276.25M$207.67M$127.09M$88.88M$108.02M$23.69M
Total Liabilities$146.92M$139.66M$193.98M$196.49M$135.08M$119.42M$100.90M$69.11M$67.69M$28.14M
Shareholders' Equity$477.32M$349.02M$135.21M$151.97M$141.17M$88.25M$26.19M$19.77M$40.33M-$4.46M
Cash & Equivalents$87.63M$103.15M$51.35M$86.52M$51.09M$55.92M$26.75M$26.75M$43.11M$9.91M
Operating Cash Flow$50.40M$118.67M$8.80M-$59.51M-$112.37M-$102.00M-$76.19M-$62.68M-$37.27M-$18.27M
Capital Expenditures$22.57M$8.23M$4.77M$13.91M$13.51M$12.73M$3.81M$2.10M$2.68M$73.4K
Shares Outstanding237.87M236.62M226.06M221.82M195.81M104.90M59.32M46.35M36.73M12.89M